Onconetix, Inc. (ONCO) - Halal (Shariah-Compliant)
Onconetix, Inc. (ONCO) is classified as Halal (Shariah-Compliant) according to AAOIFI Shariah screening standards. This assessment is based on business activity screening and financial ratio analysis using the AAOIFI methodology.
Business Activity Screen
- Sector
- Healthcare
- Industry
- Biotechnology
- Result
- Pass
- Reason
- The sector "Healthcare" and industry "Biotechnology" are not in the excluded categories.
Financial Ratios
- Debt Ratio
- Value: 0.0% | Threshold: 30% | Result: Pass
- Cash & Interest-bearing Securities Ratio
- Value: 1.5% | Threshold: 30% | Result: Pass
- Non-Permissible Income Ratio
- Value: 0.0% | Threshold: 5% | Result: Pass
Dividend Purification
Purification percentage: 0.00%.Based on the company's financial statements, approximately 0.00% of dividend income should be donated to charity for purification. This is derived from identified interest income (0.00% of total income). Some scholars may differ on the exact calculation method.
About Onconetix, Inc.
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
Frequently Asked Questions
Is Onconetix, Inc. (ONCO) stock halal to invest in?
According to AAOIFI Shariah screening standards, Onconetix, Inc. (ONCO) is currently classified as Halal (Shariah-Compliant). This is based on both business activity and financial ratio screening.
Does Onconetix, Inc. have any interest income?
Onconetix, Inc.'s interest income ratio is 1.5% of total revenue. AAOIFI standards require this to be below 30%.

